FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804482009> ?p ?o ?g. }

• W2804482009 endingPage "26208" @default.
• W2804482009 startingPage "26195" @default.
• W2804482009 abstract "// Jan Nyrop Jakobsen 1, * , Eric Santoni-Rugiu 2, * , Morten Grauslund 2 , Linea Melchior 2 and Jens Benn Sørensen 1 1 Department of Oncology, Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark 2 Department of Pathology, Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark * Equal first authors Correspondence to: Jan Nyrop Jakobsen, email: jan.nyrop.jakobsen@regionh.dk Eric Santoni-Rugiu, email: eric.santoni-rugiu.02@regionh.dk Keywords: NSCLC; EGFR; erlotinib; tarceva; mutation Received: February 19, 2018      Accepted: May 05, 2018      Published: May 25, 2018 ABSTRACT Background: Patients with EGFR -mutated non-small-cell lung cancer benefit from EGFR tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by driver mutations in other genes. Methods: Five hundred and fourteen consecutive patients with NSCLC of all stages were tested for EGFR -mutations by cobas® EGFR Mutation Test. Fluorescent in situ hybridization (FISH) for MET -amplification, immunohistochemistry (IHC) for MET- and ALK-expression, and Next Generation Sequencing (NGS) for concomitant driver mutations were performed on EGFR -mutated tumor samples from erlotinib-treated patients. Results: Thirty-six patients (7%) had EGFR -mutations, including 2 with intrinsic resistance mutation p.T790M together with the p.L858R sensitizing mutation and 1 harboring the p.G719C/S768I double-mutation. Twenty-three patients had either locally advanced or advanced disease and received first-line erlotinib-treatment. Concomitant driver mutations were found in 15/21 (71%) of NGS-analyzed TKI-treated NSCLCs, involving in 67% of cases TP53 , in 13% CTNNB1 , and in 7% KRAS , MET , SMAD4 , PIK3CA , FGFR1 , FGFR3 , NRAS, DDR2 , and ERBB4 . No ALK-expression was found, whereas MET-overexpression and MET -amplification were observed in 5 and 4 patients, respectively. Objective responses occurred in 17/23 patients (74%), 4 did not respond (17%), and 2 harboring a SMAD4 -mutation (p.R135 * (stop)) and a FGFR3 -mutation (p.D785fs * 31), respectively, displayed mixed response with simultaneously progressing and responding tumors (8.7%). Thus, EGFR -mutated tumors harboring co-mutations were not less likely to respond. Conclusion: Co-mutations in other cancer-driver genes (oncogenes or tumor suppressor genes) were frequent in EGFR -mutated NSCLCs and few cases harbored concomitant activating and resistance EGFR -mutations before TKI-treatment. Most co-mutations did not impact the response to first-line erlotinib-treatment, but may represent potential additional therapeutic targets." @default.
• W2804482009 created "2018-06-01" @default.
• W2804482009 creator A5033396141 @default.
• W2804482009 creator A5041377715 @default.
• W2804482009 creator A5055100219 @default.
• W2804482009 creator A5058748910 @default.
• W2804482009 creator A5079045120 @default.
• W2804482009 date "2018-05-25" @default.
• W2804482009 modified "2023-09-28" @default.
• W2804482009 title "Concomitant driver mutations in advanced <i>EGFR</i>-mutated non-small-cell lung cancer and their impact on erlotinib treatment" @default.
• W2804482009 cites W1931481736 @default.
• W2804482009 cites W1960850967 @default.
• W2804482009 cites W1985644369 @default.
• W2804482009 cites W1987709860 @default.
• W2804482009 cites W1988717076 @default.
• W2804482009 cites W1998971866 @default.
• W2804482009 cites W2001691361 @default.
• W2804482009 cites W2007118438 @default.
• W2804482009 cites W2009629707 @default.
• W2804482009 cites W2009775937 @default.
• W2804482009 cites W2019607817 @default.
• W2804482009 cites W2020534880 @default.
• W2804482009 cites W2031570350 @default.
• W2804482009 cites W2050267177 @default.
• W2804482009 cites W2052378862 @default.
• W2804482009 cites W2060575051 @default.
• W2804482009 cites W2062629045 @default.
• W2804482009 cites W2077224394 @default.
• W2804482009 cites W2098599074 @default.
• W2804482009 cites W2098674632 @default.
• W2804482009 cites W2110540279 @default.
• W2804482009 cites W2122319990 @default.
• W2804482009 cites W2122442582 @default.
• W2804482009 cites W2125486087 @default.
• W2804482009 cites W2127990562 @default.
• W2804482009 cites W2130256619 @default.
• W2804482009 cites W2131088620 @default.
• W2804482009 cites W2131323155 @default.
• W2804482009 cites W2139804581 @default.
• W2804482009 cites W2158797210 @default.
• W2804482009 cites W2161869130 @default.
• W2804482009 cites W2168977308 @default.
• W2804482009 cites W2170899818 @default.
• W2804482009 cites W2171755671 @default.
• W2804482009 cites W2172010139 @default.
• W2804482009 cites W2180481128 @default.
• W2804482009 cites W2193719724 @default.
• W2804482009 cites W2251438188 @default.
• W2804482009 cites W2270997383 @default.
• W2804482009 cites W2271852462 @default.
• W2804482009 cites W2281689329 @default.
• W2804482009 cites W2300085745 @default.
• W2804482009 cites W2336491212 @default.
• W2804482009 cites W2336809232 @default.
• W2804482009 cites W2340056105 @default.
• W2804482009 cites W2352491315 @default.
• W2804482009 cites W2398778057 @default.
• W2804482009 cites W2418808650 @default.
• W2804482009 cites W2469255185 @default.
• W2804482009 cites W2472019910 @default.
• W2804482009 cites W2519152232 @default.
• W2804482009 cites W2534288116 @default.
• W2804482009 cites W2561330651 @default.
• W2804482009 cites W2564183684 @default.
• W2804482009 cites W2566209015 @default.
• W2804482009 cites W2581103010 @default.
• W2804482009 cites W2586439898 @default.
• W2804482009 cites W2593252256 @default.
• W2804482009 cites W2603411876 @default.
• W2804482009 cites W2655216406 @default.
• W2804482009 cites W2734669213 @default.
• W2804482009 cites W2752876052 @default.
• W2804482009 doi "https://doi.org/10.18632/oncotarget.25490" @default.
• W2804482009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5995236" @default.
• W2804482009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29899852" @default.
• W2804482009 hasPublicationYear "2018" @default.
• W2804482009 type Work @default.
• W2804482009 sameAs 2804482009 @default.
• W2804482009 citedByCount "33" @default.
• W2804482009 countsByYear W28044820092018 @default.
• W2804482009 countsByYear W28044820092019 @default.
• W2804482009 countsByYear W28044820092020 @default.
• W2804482009 countsByYear W28044820092021 @default.
• W2804482009 countsByYear W28044820092022 @default.
• W2804482009 countsByYear W28044820092023 @default.
• W2804482009 crossrefType "journal-article" @default.
• W2804482009 hasAuthorship W2804482009A5033396141 @default.
• W2804482009 hasAuthorship W2804482009A5041377715 @default.
• W2804482009 hasAuthorship W2804482009A5055100219 @default.
• W2804482009 hasAuthorship W2804482009A5058748910 @default.
• W2804482009 hasAuthorship W2804482009A5079045120 @default.
• W2804482009 hasBestOaLocation W28044820091 @default.
• W2804482009 hasConcept C104317684 @default.
• W2804482009 hasConcept C121608353 @default.
• W2804482009 hasConcept C126322002 @default.
• W2804482009 hasConcept C143998085 @default.
• W2804482009 hasConcept C2776256026 @default.
• W2804482009 hasConcept C2777930144 @default.

• next